CTOs on the Move

Q S Pharma

www.qspharma.com

 
Q S Pharma LLC is a Marcus Hook, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.qspharma.com
  • 3 Chelsea Pkwy Ste 305
    Marcus Hook, PA USA 19061
  • Phone: 610.485.4270

Executives

Name Title Contact Details

Similar Companies

Cosmetic Essence, Inc.

Cosmetic Essence, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Holmdel, NJ. To find more information about Cosmetic Essence, Inc., please visit www.cosmeticessence.com

CLS Holdings USA,

Cannabis Life Sciences is both a cannabis producer and retailer offering a wide variety of products through its brands, Oasis and City Trees.

AZTherapies, Inc.

AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions.

Johns Hopkins Bayview Medical

Johns Hopkins Bayview Medical is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.